A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years.

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting transcription-replication conflicts to combat treatment resistance.

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S.

Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...

A review paper published last year in European Journal of Medicinal Chemistry characterized Myc as the “oncogene from ...

Reference: Vinaixa J, Martínez-Bosch N, Gibert J, et al. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. PNAS. 2025;122(14):e2424051122. doi: ...

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and genome duplication collide.

The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen ...

Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2424051122. doi: 10.1073/pnas.2424051122. Epub 2025 Apr 2.